ArticleWorld journal of urology2026
Risk factors for seminal vesicle invasion at radical prostatectomy.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo comprehensively assess predictors of seminal vesicle invasion (SVI) at radical prostatectomy given the low sensitivity of magnetic resonance imaging (MRI).
methodsBetween 2017 and 2025, 4,448 patients underwent radical prostatectomy alone. Multivariable logistic regression was used to identify clinicopathological and MRI-related predictors of pathologic SVI, including age, Black race, PSA, PSA density, clinical T stage, Grade Group, percentage of positive cores, basal tumor involvement on systematic biopsy, the location of PI-RADS 4/5 lesions (apex/midgland/base), and MRI-suspected extracapsular extension and SVI. The same variables were evaluated in patients without MRI-detected SVI (n = 4,358). Model discrimination was assessed using the AUC.
resultsPathologic SVI prevalence was 6.9% (305/4,448). MRI demonstrated 17% sensitivity and 99% specificity. Independent clinicopathological predictors (all p < 0.04) were Black race (OR 1.48), log-PSA (OR 2.30/1-unit), Grade Groups 3–5 (OR 2.56–4.32), percentage of positive cores (OR 1.21/10%), and basal tumor involvement on biopsy (OR 1.92). MRI-related independent predictors (all p < 0.01) were SVI (OR 15.7), extracapsular extension (OR 1.69), and midgland (OR 1.49) and basal (OR 1.92) PI-RADS 4/5 lesions; apex lesions were inversely associated (OR 0.64). These associations remained significant in the MRI-negative subgroup. The model showed good discrimination (AUC 0.80, 95% CI 0.77–0.82), remaining robust in MRI-negative patients (AUC 0.76, 95% CI 0.73–0.79). Limitation included selection bias toward favorable-risk features by excluding patients with hormonal therapy.
conclusionMultifactorial risk assessment, particularly including tumor location, helps mitigate MRI’s limited sensitivity for SVI detection and could inform surgical or radiation planning in patients at risk of SVI.
Indexed as
Identifiers
41964892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.